Expert discussant panel at the #AmyloidosisForum with the @FDA - all committed to reliable scientific advancement in #Amyloidosis - including @vsanchorawala from @BU_Amyloidosis.
1
147
Isabelle Lousada and Kristen Hsu of @Amyloidosis_ARC kicking off the Amyloidosis Forum at the @FDA - accelerating drug development in amyloidosis.
2
130
Andrew Staron retweeted
Exciting day at @US_FDA brainstorming prognostic factors and clinical trial endpoints in AL Amyloidosis!
Dr. @rajshekharucms presenting the #AmyloidosisForum Prognostic Factors working group's plans to develop prognostic factors for clinical trial endpoints with quantitative assessments and validation that reflects current standards of care in #amyloidosis
Andrew Staron retweeted
As the event comes to a close, we want to express our gratitude to our dedicated multidisciplinary team members for sharing their research during the conference. #ISA2024 #Amyloidosis @ISA_Amyloidosis
Andrew Staron retweeted
💙Masterclass in Cardiac #Amyloidosis @MyASNC @NotNoninvasive @LPhillipsMD
Day 1⃣⭐️ Prognostic markers in amyloidosis by Andrew Staron @a_staron @BU_Amyloidosis
👉ATTR
Andrew Staron retweeted
While we usually shrug it off as insignificant, the loss of the Y chromosome (mLOY) in men is associated with a much higher cancer mortality, CV mortality and all cause mortality than those without it.
Possible association with ATTR amyloidosis.
@BU_Amyloidosis
Andrew Staron retweeted
Significant and exciting news! Nexcella Announces FDA Approval of IND Application for CAR-T NXC-201. With this clearance, NEXICART-2 (NCT06097832) is to expand studies of NXC-201 in relapsed/refractory AL amyloidosis to the US. @BU_Amyloidosis
nexcella.com/2023/11/21/nexc…
Andrew Staron retweeted
Increase awareness, decrease educational gap to diagnose early and improve outcomes. High clinical index of suspicion when red flag symptoms/signs/syndromes present is crucial.
Andrew Staron retweeted
Avoid implicit bias in amyloidosis & never skip genetic testing, particularly in minority groups. At @BU_Amyloidosis, 7 self-identified white patients with ATTRV122I and 19 self-identified Black patients with ATTRwt. The presentation of amyloidosis is truly diverse! @a_staron
Andrew Staron retweeted
February is Rare Disease Awareness Month! This month is all about public, medical, & political #amyloidosisawareness. Not only is it critical to let more people know about diagnostics and treatments that already exist but to create momentum for the development of new discoveries.
Andrew Staron retweeted
Do not start plasma cell directed therapies till diagnosis of AL Amyloidosis is confirmed by accurate identification of the precursor protein #ASH22 #amyloidosis @Amyloid_Planet
Andrew Staron retweeted
Daratumumab in AL amyloidosis
@awechalekar
ashpublications.org/blood/ar…
Andrew Staron retweeted
Save the date to hear from four of our incredible @BU_Amyloidosis clinicians during a live webinar hosted by @Amyloidosisfdn! Register for Updates in ATTR Cardiac and Neurological Amyloidosis at 12:00 pm ET on Friday, October 28 by visiting pathlms.com/amyloidosis/webi…
Andrew Staron retweeted
We're excited to share our report on apoptotic vulnerabilities in AL amyloidosis. We analyzed over 50 primary specimens from AL patients at @BU_Amyloidosis and find that clonal plasma cells are frequently dependent on BCL-2 or MCL-1 for survival. (1/n) nature.com/articles/s41467-0…
Andrew Staron retweeted
1/3:Absolutely need PYP or tissue to start treatment for cardiac #amyloidosis. There are many mimickers by both echo and CMR with variability in quality, technical issues, and interpretation in both, especially outside of amyloid centers.
Replying to @MarthaGrogan1
If the echo and MRI are consistent with amyloid (and AL excluded), is a PYP scan really needed prior to starting therapy? Is there data on diagnostic benefit on top of MRI? @BrettSperryMD
Home safe after a long day of travel! Thank you Heidelberg for showing your picturesque cobble streets and hospitality. Lots of great science to digest. But first, a morning run to burn off the week's schnitzels and potatoes. Missed you Boston!
11
Andrew Staron retweeted
Exciting meeting #ISA_2022. The future of diagnostics and therapeutics of Amyloidosis is bright with engagement of all stakeholders. Congratulations to Dr Schonland and @UHegenbart for organizing a very stimulating flawless meeting @BU_Amyloidosis
Andrew Staron retweeted
Great work by @SaelicesL determining multiple ATTR fibril structures #ISA_2022





























